Cosentyx (secukinumab) - Novartis
In recently relapsed polymyalgia rheumatica during GC tapering, secukinumab increased sustained remission rates at 1 y. (PubMed, Ann Intern Med) - Oct 6, 2026 - "GIM/FP/GP: [Formula: see text] Rheumatology: [Formula: see text]." 
Journal • Immunology • Musculoskeletal Pain • Pain • Polymyalgia Rheumatica • Rheumatology
http://www.ncbi.nlm.nih.gov/pubmed/42832794
 
; David S Pisetsky
 
Oct 6, 2026
 
Prev Next